Annual EBITDA
-$57.09 M
-$34.58 M-153.60%
31 December 2023
Summary:
BioLineRx annual earnings before interest, taxes, depreciation & amortization is currently -$57.09 million, with the most recent change of -$34.58 million (-153.60%) on 31 December 2023. During the last 3 years, it has fallen by -$29.47 million (-106.71%). BLRX annual EBITDA is now -1454.54% below its all-time high of $4.21 million, reached on 31 December 2010.BLRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.36 M
-$6.40 M-210.25%
30 September 2024
Summary:
BioLineRx quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.36 million, with the most recent change of -$6.40 million (-210.25%) on 30 September 2024. Over the past year, it has increased by +$11.61 million (+77.57%). BLRX quarterly EBITDA is now -115.99% below its all-time high of $20.99 million, reached on 30 September 2010.BLRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$13.32 M
+$11.61 M+46.57%
30 September 2024
Summary:
BioLineRx TTM earnings before interest, taxes, depreciation & amortization is currently -$13.32 million, with the most recent change of +$11.61 million (+46.57%) on 30 September 2024. Over the past year, it has increased by +$34.22 million (+71.99%). BLRX TTM EBITDA is now -241.51% below its all-time high of $9.41 million, reached on 30 June 2011.BLRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BLRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -153.6% | +77.6% | +72.0% |
| 3 y3 years | -106.7% | +36.5% | +59.5% |
| 5 y5 years | -158.0% | -7.8% | +29.2% |
BLRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -153.6% | at low | -210.3% | +80.3% | at high | +76.7% |
| 5 y | 5 years | -158.0% | at low | -210.3% | +80.3% | at high | +76.7% |
| alltime | all time | -1454.5% | at low | -116.0% | +80.3% | -241.5% | +76.7% |
BioLineRx EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.36 M(-210.2%) | -$13.32 M(-46.6%) |
| June 2024 | - | $3.04 M(+169.5%) | -$24.93 M(-44.6%) |
| Mar 2024 | - | $1.13 M(-108.0%) | -$44.98 M(-21.2%) |
| Dec 2023 | -$57.09 M(+153.6%) | -$14.14 M(-5.5%) | -$57.09 M(+20.1%) |
| Sept 2023 | - | -$14.96 M(-12.0%) | -$47.54 M(+21.9%) |
| June 2023 | - | -$17.01 M(+55.0%) | -$39.00 M(+34.9%) |
| Mar 2023 | - | -$10.98 M(+139.1%) | -$28.92 M(+28.5%) |
| Dec 2022 | -$22.51 M(-11.3%) | -$4.59 M(-28.6%) | -$22.51 M(+2.9%) |
| Sept 2022 | - | -$6.43 M(-7.2%) | -$21.87 M(+5.5%) |
| June 2022 | - | -$6.92 M(+51.5%) | -$20.73 M(+2.5%) |
| Mar 2022 | - | -$4.57 M(+15.8%) | -$20.23 M(-20.3%) |
| Dec 2021 | -$25.37 M(-8.1%) | -$3.95 M(-25.3%) | -$25.37 M(-22.8%) |
| Sept 2021 | - | -$5.29 M(-17.6%) | -$32.85 M(+3.7%) |
| June 2021 | - | -$6.42 M(-33.9%) | -$31.68 M(+0.8%) |
| Mar 2021 | - | -$9.71 M(-15.1%) | -$31.42 M(+13.8%) |
| Dec 2020 | -$27.62 M(+24.1%) | -$11.43 M(+178.0%) | -$27.62 M(+10.4%) |
| Sept 2020 | - | -$4.11 M(-33.3%) | -$25.01 M(+4.2%) |
| June 2020 | - | -$6.16 M(+4.3%) | -$24.01 M(+5.9%) |
| Mar 2020 | - | -$5.91 M(-33.0%) | -$22.67 M(+1.9%) |
| Dec 2019 | -$22.25 M(+0.6%) | -$8.83 M(+183.5%) | -$22.25 M(+18.3%) |
| Sept 2019 | - | -$3.11 M(-35.4%) | -$18.80 M(-14.1%) |
| June 2019 | - | -$4.82 M(-12.3%) | -$21.88 M(+0.9%) |
| Mar 2019 | - | -$5.50 M(+2.2%) | -$21.69 M(-1.6%) |
| Dec 2018 | -$22.13 M(-7.3%) | -$5.38 M(-13.1%) | -$22.05 M(-7.9%) |
| Sept 2018 | - | -$6.19 M(+33.7%) | -$23.94 M(-3.7%) |
| June 2018 | - | -$4.63 M(-20.9%) | -$24.86 M(-0.5%) |
| Mar 2018 | - | -$5.85 M(-19.5%) | -$24.99 M(+4.7%) |
| Dec 2017 | -$23.87 M | -$7.27 M(+2.3%) | -$23.87 M(+11.3%) |
| Sept 2017 | - | -$7.11 M(+49.2%) | -$21.45 M(+15.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$4.76 M(+0.7%) | -$18.55 M(+6.6%) |
| Mar 2017 | - | -$4.73 M(-2.6%) | -$17.40 M(+8.5%) |
| Dec 2016 | -$16.03 M(+1.8%) | -$4.86 M(+15.4%) | -$16.03 M(-3.5%) |
| Sept 2016 | - | -$4.21 M(+16.6%) | -$16.62 M(+20.3%) |
| June 2016 | - | -$3.61 M(+7.3%) | -$13.82 M(-7.4%) |
| Mar 2016 | - | -$3.36 M(-38.2%) | -$14.93 M(-5.3%) |
| Dec 2015 | -$15.76 M(-7.2%) | -$5.44 M(+286.4%) | -$15.76 M(-25.0%) |
| Sept 2015 | - | -$1.41 M(-70.1%) | -$21.02 M(+3.9%) |
| June 2015 | - | -$4.71 M(+12.5%) | -$20.24 M(+6.0%) |
| Mar 2015 | - | -$4.19 M(-60.8%) | -$19.09 M(+13.2%) |
| Dec 2014 | -$16.99 M(+1.8%) | -$10.70 M(+1604.0%) | -$16.86 M(+43.2%) |
| Sept 2014 | - | -$628.00 K(-82.4%) | -$11.77 M(-23.9%) |
| June 2014 | - | -$3.56 M(+81.6%) | -$15.46 M(-1.0%) |
| Mar 2014 | - | -$1.96 M(-65.1%) | -$15.62 M(-5.5%) |
| Dec 2013 | -$16.69 M(-22.1%) | -$5.62 M(+30.1%) | -$16.53 M(-19.4%) |
| Sept 2013 | - | -$4.32 M(+16.0%) | -$20.51 M(-4.2%) |
| June 2013 | - | -$3.72 M(+29.4%) | -$21.41 M(+4.8%) |
| Mar 2013 | - | -$2.88 M(-70.0%) | -$20.44 M(-5.7%) |
| Dec 2012 | -$21.42 M(+42.8%) | -$9.59 M(+83.6%) | -$21.68 M(+13.7%) |
| Sept 2012 | - | -$5.22 M(+90.0%) | -$19.06 M(+20.1%) |
| June 2012 | - | -$2.75 M(-33.2%) | -$15.87 M(-8.8%) |
| Mar 2012 | - | -$4.12 M(-40.9%) | -$17.41 M(+10.8%) |
| Dec 2011 | -$15.00 M(-455.9%) | -$6.97 M(+242.9%) | -$15.71 M(+15.4%) |
| Sept 2011 | - | -$2.03 M(-52.6%) | -$13.62 M(-244.7%) |
| June 2011 | - | -$4.29 M(+77.1%) | $9.41 M(+60.4%) |
| Mar 2011 | - | -$2.42 M(-50.4%) | $5.87 M(+31.5%) |
| Dec 2010 | $4.21 M | -$4.88 M(-123.2%) | $4.46 M(-52.2%) |
| Sept 2010 | - | $20.99 M(-368.1%) | $9.34 M(-180.1%) |
| June 2010 | - | -$7.83 M(+104.7%) | -$11.66 M(+204.7%) |
| Mar 2010 | - | -$3.83 M | -$3.83 M |
FAQ
- What is BioLineRx annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for BioLineRx?
- What is BioLineRx annual EBITDA year-on-year change?
- What is BioLineRx quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for BioLineRx?
- What is BioLineRx quarterly EBITDA year-on-year change?
- What is BioLineRx TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for BioLineRx?
- What is BioLineRx TTM EBITDA year-on-year change?
What is BioLineRx annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BLRX is -$57.09 M
What is the all time high annual EBITDA for BioLineRx?
BioLineRx all-time high annual earnings before interest, taxes, depreciation & amortization is $4.21 M
What is BioLineRx annual EBITDA year-on-year change?
Over the past year, BLRX annual earnings before interest, taxes, depreciation & amortization has changed by -$34.58 M (-153.60%)
What is BioLineRx quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BLRX is -$3.36 M
What is the all time high quarterly EBITDA for BioLineRx?
BioLineRx all-time high quarterly earnings before interest, taxes, depreciation & amortization is $20.99 M
What is BioLineRx quarterly EBITDA year-on-year change?
Over the past year, BLRX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$11.61 M (+77.57%)
What is BioLineRx TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BLRX is -$13.32 M
What is the all time high TTM EBITDA for BioLineRx?
BioLineRx all-time high TTM earnings before interest, taxes, depreciation & amortization is $9.41 M
What is BioLineRx TTM EBITDA year-on-year change?
Over the past year, BLRX TTM earnings before interest, taxes, depreciation & amortization has changed by +$34.22 M (+71.99%)